Bottom line
FBIOX vs PBE: the short answer
FBIOX (Biotechnology Portfolio) and PBE (Invesco Biotechnology & Genome ETF) are both mutual funds.
But FBIOX is far broader, holding 215 positions to 33 for PBE, so beyond the top names it adds exposure PBE doesn't have.
PBE is cheaper at 0.59% vs 0.62% — a difference of $3.00 a year per $10,000 invested.
Over five years, FBIOX returned +3.5% a year vs +3.4% for PBE (reporting dates differ).
Updated Nov 19, 2026
FBIOX vs PBE side by side
| FBIOX | PBE | |
|---|---|---|
| Type | Mutual fund | ETF |
| Fund family | Fidelity | Invesco |
| Category | Technology Sector | Technology Sector |
| Expense ratio | 0.62% | 0.59% |
| Annual cost per $10k | $62 | $59 |
| 10-yr cost on $10k (prospectus) | $774 | $738 |
| Max front load | — | None |
| 12b-1 fee | 0% | — |
| 1-yr return | +36.4% | +24.7% |
| 5-yr return (annualized) | +3.5% | +3.4% |
| 10-yr return (annualized) | +6.9% | +5.2% |
| Best quarter | +33.6% | +25.3% |
| Worst quarter | −28.4% | −24.3% |
| Net assets (fund) | $5.3B | $281.9M |
| Number of holdings | 215 | 33 |
| Portfolio turnover | 45% | 103% |
| Returns as of | Apr 30, 2026 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | FBIOX | PBE | Difference |
|---|---|---|---|
| 2025 | +36.4% | +24.7% | +11.7% |
| 2024 | +7.3% | +1.1% | +6.2% |
| 2023 | +10.1% | +3.7% | +6.4% |
| 2022 | −15.9% | −10.8% | −5.1% |
| 2021 | −12.4% | +1.6% | −13.9% |
| 2020 | +38.3% | +25.5% | +12.8% |
| 2019 | +36.0% | +18.3% | +17.7% |
| 2018 | −10.7% | +0.2% | −11.0% |
| 2017 | +27.9% | +22.4% | +5.4% |
| 2016 | −23.7% | −23.0% | −0.7% |
Source: Fund prospectus bar charts
Holdings overlap
5 of FBIOX's top 25 holdings also appear in PBE's top 25.
| Holding | FBIOX | PBE |
|---|---|---|
| Amgen Inc | 6.53% | 5.22% |
| Gilead Sciences Inc | 4.82% | 4.43% |
| Alnylam Pharmaceuticals Inc | 2.93% | 3.17% |
| Biogen Inc | 1.26% | 4.79% |
| Protagonist Therapeutics Inc | 1.15% | 3.40% |
Source: SEC Form N-PORT
FBIOX top 10
- Krystal Biotech Inc — 10.58%
- Abbvie Inc — 9.22%
- Amgen Inc — 6.53%
- Gilead Sciences Inc — 4.82%
- Fidelity Revere Street Trust — 3.35%
- Alnylam Pharmaceuticals Inc — 2.93%
- Praxis Precision Medicines Inc. — 2.47%
- Insmed Inc — 2.25%
- Argenx Se — 2.25%
- Ascendis Pharma A/s — 2.04%
PBE top 10
- Invesco Private Prime Fund — 12.89%
- Regeneron Pharmaceuticals, Inc. — 5.47%
- Amgen Inc. — 5.22%
- CareDx, Inc. — 5.04%
- Vertex Pharmaceuticals Inc. — 4.99%
- Invesco Private Government Fund — 4.97%
- Royalty Pharma PLC — 4.94%
- Biogen Inc. — 4.79%
- Gilead Sciences, Inc. — 4.43%
- United Therapeutics Corp. — 4.08%
FAQ
What is the difference between FBIOX and PBE?
Which is cheaper, FBIOX or PBE?
Should I own both FBIOX and PBE?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.